ClinicalTrials.gg

Program

PF-07985631

A development code.

Its studies are led by Pfizer.

Furthest: phase 1, since May 20, 20252 company-led studies, 1 open or runningNext primary completion: Dec 12, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer21 open or runningphase 1since May 20, 2025May 20, 2025Dec 12, 2026phase 1 · NCT06994897

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2025First study: phase 1 study in HealthyFirst studyNCT06994897 · 26 enrolled · Belgium
  2. Nov 14, 2025Phase 1 study in HealthyNCT07235150 · 9 enrolled · Australia

Ahead

  1. Dec 12, 2026Primary completion: phase 1 study in HealthyNCT06994897

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07235150Healthy · Australia1TerminatedJul 16, 20269
NCT06994897Healthy · Belgium1Active, not recruitingDec 12, 202626

How it is read

Names in the registry

  • “PF-07985631”, 2 entries

Codes read as this program: PF07985631.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.